Home > Journals > International Angiology > Past Issues > International Angiology 2008 August;27(4) > International Angiology 2008 August;27(4):296-301

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

INTERNATIONAL ANGIOLOGY

A Journal on Angiology


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899


eTOC

 

Original articles  


International Angiology 2008 August;27(4):296-301

language: English

Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study

Gosk-Bierska I. 1, Wysokinski W. 2, Karnicki K. 2, Adamiec R. 1

1 Unit of Angiology, Hypertension and Diabetology, Medical University of Wroc⁄law, Wroc⁄law, Poland
2 Mayo Clinic and Foundation for Education and Research, Rochester, MN, USA


PDF  


Aim. Thrombus formation plays a critical role in pathogenesis of cardiovascular complications in atherosclerotic peripheral arterial occlusive disease (PAOD). Tissue factor (TF) initiates the clotting cascade and is considered an important regulator of hemostasis and thrombosis. TF activity is regulated by TF pathway inhibitor (TFPI). The aim of our study was to evaluate plasma levels of the TF, TFPI and their relation to coagulation system and various other risk factors of atherosclerosis in patients with chronic limbs ischemia.
Methods. Plasma TF, total TFPI, truncated TFPI, full-length TFPI were assessed by ELISA using commercially available kits (IMUBIND Tissue Factor; Total TFPI; Truncated TFPI ELISA Kit; American Diagnostica Inc. Stamford) in 62 claudicant patients with PAOD and 20 healthy controls.
Results. We observed statistically higher levels of TF (94±52 pg/mL), total TFPI (43±8 ng/mL), and truncated TFPI (22±7 ng/mL) in patients with PAOD compared to healthy individuals (TF: 66±15 pg/mL; total TFPI: 36±4 ng/mL; truncated TFPI: 14±5 ng/mL). Full-length TFPI (20±4 ng/mL) is lower in patients with PAOD than in controls (23±5 ng/mL). The study indicated a positive correlation between TF and truncated TFPI (r=0.34), total TFPI and full TFPI (r=0.5), total TFPI and truncated TFPI (r=0.83) in patients with PAOD, and negative correlation between full TFPI and truncated TFPI (r=-0.65) in the control.
Conclusion. Elevated levels of TF, disorders of balance between full-length TFPI and truncated TFPI as well as significantly increased truncated TFPI level in patients with PAOD can be independent risk factors of atherosclerotic complications.

top of page

Publication History

Cite this article as

Corresponding author e-mail